Skip to content

ACCENTIA BIOPHARMACEUTICALS INC

Delisted

CIK 1310094fmd_1KNZQYKW8VZ7AN0T21K6646JFXManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Oct 01, 2009 to Sep 30, 2012, 10 periods

Latest annual · FY2012

Millions
Total revenues
4
Gross profit
1
Operating income
(12)
Net income
(9)
Free cash flow
(6)

Latest quarter · Q4 FY2012

Millions
Total revenues
1
Gross profit
0
Operating income
(3)
Net income
(4)
Free cash flow
(1)
Open Financials

ACCENTIA BIOPHARMACEUTICALS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2012FY2011ChangeSource
Revenue$4.1 million$4 million+2.5%10-K 2012-12-26 · proof
Gross profit$1.3 million$1.5 million-12.4%10-K 2012-12-26 · proof
Operating income-$11.5 million-$21.2 million10-K 2012-12-26 · proof
Net income-$9.2 million-$15.7 million10-K 2012-12-26 · proof
Cash from operating activities-$6.3 million-$6.1 million10-K 2012-12-26 · proof
Free cash flow-$6.4 million-$6.9 million10-K 2012-12-26 · proof
Total assets$2.6 million$5.9 million-56.3%10-K 2012-12-26 · proof
Total liabilities$82.3 million$93 million-11.5%10-K 2012-12-26 · proof
Cash and cash equivalents$129,168$420,540-69.3%10-K 2012-12-26 · proof
What was ACCENTIA BIOPHARMACEUTICALS INC's revenue in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported revenue of $4.1 million for fiscal 2012 (the year ended Sep 30, 2012), against $4 million the year before (+2.5%). Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What was ACCENTIA BIOPHARMACEUTICALS INC's gross profit in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported gross profit of $1.3 million for fiscal 2012 (the year ended Sep 30, 2012), against $1.5 million the year before (-12.4%). Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What was ACCENTIA BIOPHARMACEUTICALS INC's operating income in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported operating income of -$11.5 million for fiscal 2012 (the year ended Sep 30, 2012), against -$21.2 million the year before. Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What was ACCENTIA BIOPHARMACEUTICALS INC's net income in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported net income of -$9.2 million for fiscal 2012 (the year ended Sep 30, 2012), against -$15.7 million the year before. Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What was ACCENTIA BIOPHARMACEUTICALS INC's cash from operating activities in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported cash from operating activities of -$6.3 million for fiscal 2012 (the year ended Sep 30, 2012), against -$6.1 million the year before. Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What was ACCENTIA BIOPHARMACEUTICALS INC's free cash flow in fiscal 2012?
ACCENTIA BIOPHARMACEUTICALS INC reported free cash flow of -$6.4 million for fiscal 2012 (the year ended Sep 30, 2012), against -$6.9 million the year before. Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What are ACCENTIA BIOPHARMACEUTICALS INC's total assets?
As of Sep 30, 2012, ACCENTIA BIOPHARMACEUTICALS INC reported total assets of $2.6 million, against $5.9 million a year earlier (-56.3%). Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What are ACCENTIA BIOPHARMACEUTICALS INC's total liabilities?
As of Sep 30, 2012, ACCENTIA BIOPHARMACEUTICALS INC reported total liabilities of $82.3 million, against $93 million a year earlier (-11.5%). Source: the 10-K filed with the SEC on Dec 26, 2012. SEC
What are ACCENTIA BIOPHARMACEUTICALS INC's cash and cash equivalents?
As of Sep 30, 2012, ACCENTIA BIOPHARMACEUTICALS INC reported cash and cash equivalents of $129,168, against $420,540 a year earlier (-69.3%). Source: the 10-K filed with the SEC on Dec 26, 2012. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1310094&period_type=annual&limit=5"

Information only, not investment advice.